Erasca, Inc. (ERAS) SEC Filings & Earnings Calls

Loss of COO could disrupt operational execution during critical development phase.

“COO departure effective Nov 2, 2026; no successor named.”

Regulatory and clinical development risk

“FTD does not change approval standards; product may not demonstrate therapeutic benefits; clinical trials may be delayed or fail”

Clinical and regulatory risk: ERAS-0015 still in Phase 1; registration-enabling trials not yet initiated.

“Pipeline is early-stage; key data readouts expected in H1 2027 and H2 2026.”

Clinical trial failure risk

“We have incurred significant operating losses since inception. Our net losses were $44.1 million and $33.9 million for the three months ended June 30, 2026 and 2025, respectively.” · word for word

Dependence on future financing

“We have no other committed sources of capital. Until we can generate a sufficient amount of product revenue to finance our cash requirements, if ever, we expect to finance our future cash needs primarily through equity offerings.” · word for word

Key person dependency on new R&D head; integration risk.

“New executive appointment; no immediate risk but execution depends on leadership.”

Dilution risk from share issuance

“31,428,572 shares offered, plus option for 4,714,285 additional shares”

Clinical trial risk: small sample size, preliminary data may not hold

“N=7 at RDE; data cutoff May 25, 2026”

Clinical-stage company with no approved products or revenue

“We do not have any products approved for sale and have not generated any revenue.” · word for word

Significant operating losses and accumulated deficit

“We have incurred significant operating losses since inception. Our net losses were $183.4 million and $31.0 million for the three months ended March 31, 2026 and 2025, respectively.” · word for word

Clinical development risk: ERAS-0015 and ERAS-4001 are in early stages; data readouts in H2 2026 and H1 2027.

“Monotherapy expansion data expected in H1 2027; ERAS-4001 preliminary data expected in H2 2026.”

High cash burn rate: $150M in-process R&D expense and $27.3M R&D expenses in Q1.

“R&D expenses $27.3M; in-process R&D expense $150M.”

Litigation risk from Revolution Medicines patent and trade secret allegations

“RevMed alleged patent infringement and trade secret misappropriation; demands cease of ERAS-0015 activities”

Clinical trial risk: one Grade 3 pneumonitis leading to death

“One Grade 3 TRAE of pneumonitis progressed to Grade 5 after withdrawal of supportive care per patient decision” · word for word

Patent infringement and trade secret misappropriation allegations could halt ERAS-0015 program

“RevMed demanded immediate cessation of all making, using, offering for sale, selling, and importation of ERAS-0015 in the United States”

Potential reputational damage from comparative statements allegations

“RevMed alleged improper comparison of preclinical data of ERAS-0015 and RMC-6236 in public disclosures”

Clinical trial timeline risk; data readout delay could impact pipeline valuation.

“narrowed the time period for the anticipated Phase 1 monotherapy data readout for ERAS-0015 to no later than mid-May of 2026, from the prior guidance of the first half of 2026.” · word for word

Clinical development risk

“Clinical and preclinical development involves a lengthy and expensive process with an uncertain outcome, and the results of preclinical studies and early clinical trials are not necessarily predictive of future results.” · word for word

Capital requirement risk

“We will require substantial additional capital to finance our operations, and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our development programs.” · word for word

Competition risk

“We face significant competition from entities that have developed or may develop product candidates for cancer, including companies developing novel treatments and technology platforms.” · word for word

Clinical-stage biotech with no approved products; high dependency on pipeline success

“Company is a clinical-stage precision oncology company; no commercial products; R&D expenses $92.9M in FY2025; accumulated deficit”

Dilution from offering; reliance on cash runway for operations.

“25,875,000 shares ... net proceeds $242.7 million”

Preliminary nature of financial data; subject to change after completion of closing procedures.

“Preliminary unaudited information and management estimates, subject to completion of financial closing procedures.”

No new risk signals; standard forward-looking caution.

“Boilerplate risk factors.”

Pipeline concentration and clinical failure risk

“We do not have any products approved for sale and have not generated any revenue.” · word for word

Dilution risk from ATM program

“As of September 30, 2025, we had $200.0 million of shares available for sale under the ATM program.” · word for word

Dependence on third-party manufacturers

“We do not own or operate, and currently have no plans to establish, any manufacturing facilities.” · word for word

Clinical-stage biotech with no approved products; high dependency on pipeline success.

“Net loss $30.6M; no revenue; cash runway into H2 2028.”